Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis

被引：41

作者：

Deal, C

Gideon, J

机构：

[1] Cleveland Clin Fdn, Dept Rheumat & Immunol Dis, Ctr Osteoporosis & Metab Bone Dis, Cleveland, OH 44195 USA

[2] Blanchard Valley Med Associates, Findlay, OH USA

来源：

CLEVELAND CLINIC JOURNAL OF MEDICINE | 2003年 / 70卷 / 07期

关键词：

D O I：

10.3949/ccjm.70.7.585

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Forteo (teriparaticle of rDNA origin), a genetically engineered fragment of parathyroid hormone, is the first of a new class of drugs to treat osteoporosis. The drug's anabolic action increases bone turnover, stimulating osteoblasts to a greater extent than osteoclasts, and reducing both vertebral and nonvertebral fractures. However, a number of issues about its use remain unanswered.

引用

页码：585 / +

页数：15

共 30 条

[1] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].

Black, DM ;

Cummings, SR ;

Karpf, DB ;

Cauley, JA ;

Thompson, DE ;

Nevitt, MC ;

Bauer, DC ;

Genant, HK ;

Haskell, WL ;

Marcus, R ;

Ott, SM ;

Torner, JC ;

Quandt, SA ;

Reiss, TF ;

Ensrud, KE .

LANCET, 1996, 348 (9041) :1535-1541

[2]

Body JJ, 2001, J BONE MINER RES, V16, pS179

[3] Management of the renal patient:: Experts' recommendations and clinical algorithms on renal osteodystrophy and cardiovascular risk factors -: Foreword [J].

Cannata-Andía, J ;

Passlick-Deetjen, J ;

Ritz, E .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 :1-1

[4] Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal [J].

Cosman, F ;

Nieves, J ;

Woelfert, L ;

Formica, C ;

Gordon, S ;

Shen, V ;

Lindsay, R .

JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (05) :925-931

[5] Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial [J].

Cummings, SR ;

Black, DM ;

Thompson, DE ;

Applegate, WB ;

Barrett-Connor, E ;

Musliner, TA ;

Palermo, L ;

Prineas, R ;

Rubin, SM ;

Scott, JC ;

Vogt, T ;

Wallace, R ;

Yates, AJ ;

LaCroix, AZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (24) :2077-2082

[6]

CURRAN PG, 1991, ENDOCR REV, V12, P135, DOI 10.1210/edrv-12-2-135

[7] TOXICOLOGICAL STUDIES ON OMEPRAZOLE [J].

EKMAN, L ;

HANSSON, E ;

HAVU, N ;

CARLSSON, E ;

LUNDBERG, C .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1985, 20 :53-&

[8]

Emkey R, 2002, J BONE MINER RES, V17, pS139

[9] Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -: Results from a 3-year randomized clinical trial [J].

Ettinger, B ;

Black, DM ;

Mitlak, BH ;

Knickerbocker, RK ;

Nickelsen, T ;

Genant, HK ;

Christiansen, C ;

Delmas, PD ;

Zanchetta, JR ;

Stakkestad, J ;

Glüer, CC ;

Krueger, K ;

Cohen, FJ ;

Eckert, S ;

Ensrud, KE ;

Avioli, LV ;

Lips, P ;

Cummings, SR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :637-645

[10]

Ettinger B, 2002, J BONE MINER RES, V17, pS157

← 1 2 3 →